{"entity":{"id":"nct06663098","kind":"trial","name":"Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).","aka":["CARRY-ON"],"tldr":"A phase 2 trial of atezolizumab, carboplatin and etoposide in lung cancer, run by Gruppo Oncologico Italiano di Ricerca Clinica, now recruiting.","summary":"Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC). is a phase 2, interventional study registered as NCT06663098 by Gruppo Oncologico Italiano di Ricerca Clinica, with a registry enrolment figure of 142 participants, started 2025-01-24 and due to reach its primary completion in 2028-08-30. Interventions recorded: Atezolizumab; Carboplatin; Etoposide. Conditions listed: Extensive Stage Small Cell Lung Cancer (ES-SCLC). Primary outcome: overall survival. Lung eligibility wording from the registry: \"Diagnosis of small-cell lung cancer (SCLC) (according to WHO classification 2015) confirmed at pathology (histology or cytology)\". Sites: Italy. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT06663098","url":"https://clinicaltrials.gov/study/NCT06663098"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["extensive-stage-sclc"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","platinum","topoisomerase-inhibitors"],"targets":[],"drugs":["atezolizumab","carboplatin","etoposide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06663098","phase":"2","setting":"Continued PD-L1 Inhibition With Atezolizumab With Rechallenge Chemotherapy in Patients With Sensitive Relapse SCLC Progressing on First-line Platinum-etoposide Chemotherapy and a PD-L1 Inhibitor: CARRY-ON Study-GOIRC-01-2023","sponsor":"Gruppo Oncologico Italiano di Ricerca Clinica","enrolled":142,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06663098/","neighbours":{"cancer":[{"id":"extensive-stage-sclc","kind":"cancer","name":"Extensive-stage small-cell lung cancer","route":"/cancers/extensive-stage-sclc/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"},{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"etoposide","kind":"drug","name":"Etoposide","route":"/drugs/etoposide/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}